NASDAQ · RDNT

RadNet, Inc.

$62.19 +$0.62 (+1.00%) 1D Market open
Session Pulse Regular session 1 mentions on Wed · 1 bullish / 0 bearish tags No new SEC filings since Mon close its sector ranked 5/11 this week Full pulse →

Key Metrics

$4.84B
Market cap
P/E · TTM
$2.14B
Revenue · TTM
−$14.19M
Net income
EPS · TTM $-0.19
Dividend yield
Free cash flow
Beta · 1Y 1.05
EBITDA · TTM $193.83M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 3
    From its Mar 2 high, the share price fell 31%.

    Peak close $75.22 on Mar 2; trough close $51.87 on Jun 3. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -31%
  • Mar 6
    The stock moved -9.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 6

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$4.84B
Enterprise value$5.47B
Shares outstanding78.6M
52-wk range$50.76 – $85.84
Avg volume · 20D492.2K
Net cash −$631.14M
Book value / share$14.53
IndustryServices-Medical Laboratories
ExchangeNASDAQ
About RadNet, Inc.
IPO dateOct 31, 1994
Employees11264

RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments: Imaging Center segment and Digital Health segment. The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S2.26
P/FCF
EV/EBITDA28.23
EV/Sales2.55
Graham №

Profitability

Gross
Operating 1.5%
Net -0.7%
FCF
ROE / ROIC -1.3% · 1.3%

Financial Health

Current ratio1.17
Quick ratio
Debt / equity1.01
Debt / EBITDA 5.61
Net cash −$631.14M
Working capital$105.14M

Cash Flow · TTM

Operating CF $336.31M
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

2 / 9
Weak fundamentals · 2 of 9 signals passing

Altman Z-Score

1.7
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings